Video Experimental Relacionado
Updated: May 5, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
Distribución de la tau en el hipocampo en la tauopatía primaria relacionada con la edad: el estudio Vantaa 85+
Sara Savola1,2, Jarno Tuimala1, Ville Kivistö1
1Department of Pathology, University of Helsinki, Helsinki, Finland.
Resumen
La tauopatía primaria relacionada con la edad (PART) muestra patrones distintos de enredos neurofibrilares (NFT) en el hipocampo en comparación con la enfermedad de Alzheimer (EA). El análisis de IA reveló que PART a menudo presenta una patología CA2 NFT prominente, a diferencia de la EA.
Área de la Ciencia:
- Neuropatología
- Inteligencia artificial
- Enfermedades neurodegenerativas
Sus antecedentes:
- La enfermedad de Alzheimer (EA) se caracteriza por enredos neurofibrilares (NFT) principalmente en la corteza entorrinal (CE) y en el CA1/prosubiculum.
- Se supone que la tauopatía primaria relacionada con la edad (PART) implica una predisposición temprana a la TNF en la subregión CA2 del hipocampo.
Objetivo del estudio:
- Para diferenciar los patrones de distribución de NFT entre PART y AD utilizando IA avanzada.
- Para investigar el papel de la madurez de las NFT y del beta-amiloide (Aβ) en PART frente a AD.
Principales métodos:
- Desarrollo de un modelo de IA para reconocer y cuantificar NFT de diferentes niveles de madurez en los subcampos del hipocampo.
- Aplicación del modelo de IA a las secciones del hipocampo inmunostabilizadas por tau de 210 individuos de edad ≥ 85 años en la cohorte de Vantaa 85+.
Principales resultados:
- La AD moderada exhibió una densidad de NFT significativamente mayor en EC y CA1 en comparación con PART.
- Los índices CA2/CA1 y CA2/EC de NFT estaban inversamente asociados con la deposición de Aβ, que difiere entre PART y AD.
- Aβ exacerbó el proceso de maduración de NFT más en AD que en PART.
Conclusiones:
- El patrón de NFT predominante en CA2 se observa con mayor frecuencia en PART que en AD, aunque no exclusivamente.
- El estudio destaca distintas diferencias de distribución y maduración de NFT en el hipocampo entre PART y AD, con la ayuda del análisis de IA.
Palabras clave:
La enfermedad de AlzheimerLas demás cuentasAmiloide beta y sus derivadosInteligencia artificialDeterioro cognitivoEl hipocampodegeneración neurofibrilarTauopatía primaria relacionada con la edadel tauMás Videos Relacionados
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.1K
12:55Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
9.0K
Videos de Conceptos Relacionados
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:21Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35